Humacyte Inc (HUMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 9.6% above its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 56.8, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about HUMA
GNG News
All HUMA newsNews
HUMA Valuation
HUMA Profitability: Margins, ROIC and FCF
Humacyte (HUMA) has a gross margin of -462.6%, an operating margin of -4574.0% and a net margin of 0.0%. It posts -60.5% ROIC and a -3697.0% FCF margin.
- Gross margin
- -462.6%
- Operating margin
- -4574.0%
- Net margin
- 0.0%
- ROIC
- -60.5%
- ROE
- -1424.0%
- FCF margin
- -3697.0%
Humacyte Competitors
The companies most similar to Humacyte (HUMA) include TuHURA Biosciences, Whitehawk Therapeutics and Unicycive Therapeutics.
Sector: Healthcare
Companies most similar to HumacyteHUMA Analyst Ratings
Humacyte (HUMA) has a Buy consensus from 6 analysts: 4 Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 6
- Strong Buy
- 1
- Buy
- 3
- Hold
- 2
- Sell
- 0
- Strong Sell
- 0
HUMA Bull Case vs Bear Case
Bull case
- HUMA grew quarterly revenue 36.5% year over year.
- 66.7% of HUMA's analyst ratings are Buy or Strong Buy.
Bear case
- HUMA has a debt-to-equity ratio of 3.6x.
HUMA Earnings: Beat Rate and Next Report
Humacyte (HUMA) beat the EPS estimate in 5 of the last 8 quarters (62.5%). Its next report is expected on Mar 25, 2027.
- Beat rate
- 5 of 8 quarters (62.5%)
- Average surprise
- 22.3%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.07
HUMA Earnings Date
HUMA reports Mar 25, 2027. The date is estimated.
HUMA Earnings Call
The latest HUMA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptHUMA ETF Holders
GNG tracks 6 ETFs that hold HUMA. The largest weights:
- iShares Biotechnology ETF (IBB), 0.01% of the fund
- iShares Russell 2000 ETF (IWM), 0.01% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
- Schwab U.S. Broad Market ETF (SCHB), <0.01% of the fund
Updated Nov 10, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About HUMA
When does HUMA report earnings?
Humacyte Inc (HUMA) is expected to report earnings on Mar 25, 2027.
Does HUMA pay dividends?
Humacyte Inc (HUMA) does not currently pay a regular dividend.
What is HUMA's market cap?
Humacyte Inc (HUMA) has a market capitalization of $155.12M with a current stock price of $0.54.
HUMA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.